Singapore markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.7083-0.0021 (-0.30%)
At close: 04:00PM EDT
0.6916 -0.02 (-2.36%)
After hours: 07:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7104
Open0.7106
Bid0.6990 x 1000
Ask0.7104 x 500
Day's range0.6838 - 0.7335
52-week range0.5400 - 5.8300
Volume2,098,187
Avg. volume4,844,073
Market cap107.604M
Beta (5Y monthly)1.93
PE ratio (TTM)N/A
EPS (TTM)-0.5900
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.45
  • GlobeNewswire

    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 5, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 6,188 shares of its common stock to one new employee, consisting of stock options to purchase 4,125 shares of common stock and restricted stock units (“RSUs”) covering 2,063 s

  • PR Newswire

    Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

    Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST (fecal microbiota spores, live-brpk) capsules. This transaction, when completed, supersedes any prior agreements between Nestlé and Seres concerning VOWST. Nestlé Health Science has been the lead commercialization party for the product since its l

  • GlobeNewswire

    Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

    Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performance under a transition services agreement Future Company focus on advancement of SER-155 and other cultivated oral microbiome therapeutics for medically vulnerable patient populations with potential to address large commercial opportunities CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Seres The